Home
    • Plans Blog Contact
    MARIMED INC. logo

    MARIMED INC.

    MRMD
    Last price US$0.065
    Market cap US$27.1m
    12M price change -39.87%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Zoetis IncZTS Industry peer Amphastar PAMPH Industry peer Prestige Consumer HealthcarePBH Industry peer IQVIA Holdings IncIQV Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    MARIMED INC. Overview

    Industry: Drug Manufacturers Specialty & Generic

    Sector: Healthcare

    MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature's Heritage brand; chewable cannabis-infused mint tablet under the brand Kalm Fusion. It also provides soft and chewy baked goods and a hot chocolate mix under Bubby's Baked brand. In addition, the company offers vapes, and edible products under InHouse brand. Further, it provides company licenses its brands and product formulations, as well as leases cannabis facilities. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts. MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature's Heritage brand; chewable cannabis-infused mint tablet under the brand Kalm Fusion. It also pr Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for MARIMED INC. into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 13, 2026

    Quarterly result summary

    Revenue was $39.5M (+4% YoY). Net loss was -$3.8. Adjusted EBITDA was $3.6M (+44% YoY).

    Revenue $39.5M +4% YoY
    Net loss -$3.8 reported
    Adjusted EBITDA $3.6M +44% YoY

    What changed

    • Revenue +4% YoY to $39.5M.
    • Adjusted EBITDA +44% YoY to $3.6M.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings material Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q May 14, 2026 SEC filing 8-K May 13, 2026 SEC filing 10-K Mar 12, 2026 SEC filing 8-K Mar 11, 2026 Earnings release Earnings release Mar 11, 2026 SEC filing 10-Q Nov 06, 2025 SEC filing 8-K Nov 05, 2025 Earnings material Earnings release Nov 05, 2025 SEC filing 10-Q Aug 07, 2025 Earnings material Earnings release Aug 06, 2025 SEC filing 8-K Aug 06, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 4.00/5
    MARIMED INC. boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

    Return on Equity

    Score 3.20/5
    MARIMED INC. stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    MARIMED INC. MRMD US$27.1m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.33/5
    MARIMED INC. olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    MARIMED INC. MRMD US$27.1m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

    Leverage

    Score 1.67/5
    MARIMED INC. registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    MARIMED INC. MRMD US$27.1m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    MARIMED INC. logo

    MARIMED INC.

    US$0.065

    US$0.0262

    -59.6% vs price

    US$27.1m

    -1.52%

    -39.87%